PDCD1 and head and neck squamous cell carcinoma: During recent years, immunotherapy in the form of programmed cell death protein 1 (PD-1) inhibitors has also been approved as treatment for patients with recurrent or metastatic HNSCC in several countries (Johnson et al., 2020).